{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:56Z","timestamp":1786988036043,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejca.2024.114105","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T02:02:42Z","timestamp":1714960962000},"page":"114105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Health-related quality of life in trials with high rates of early censoring: Caution advised"],"prefix":"10.1016","volume":"205","author":[{"given":"Timoth\u00e9e","family":"Olivier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2024.114105_bib1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-020-0368-0","article-title":"Informative censoring \u2014 a neglected cause of bias in oncology trials","volume":"17","author":"Templeton","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114105_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2020.09.031","article-title":"Censored patients in Kaplan\u2013Meier plots of cancer drugs: an empirical analysis of data sharing","volume":"141","author":"Rosen","year":"2020","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.ejca.2024.114105_bib3","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.ejca.2015.07.005","article-title":"The role of censoring on progression free survival: oncologist discretion advised","volume":"51","author":"Prasad","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114105_bib4","article-title":"Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer: limitations of the VISION trial","author":"Olivier","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2024.114105_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113942","article-title":"Equal censoring but still informative: when the reasons for censoring differ between treatment arms","volume":"201","author":"Olivier","year":"2024","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.114105_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114105_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jclinepi.2021.07.013","article-title":"Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials","volume":"139","author":"Olivier","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.ejca.2024.114105_bib8","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114105_bib9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2024.114105_bib10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1634\/theoncologist.2015-0478","article-title":"Sorafenib effectiveness in advanced hepatocellular carcinoma","volume":"21","author":"Sanoff","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ejca.2024.114105_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100480","article-title":"Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm?","volume":"7","author":"Haslam","year":"2022","journal-title":"ESMO Open"},{"issue":"20","key":"10.1016\/j.ejca.2024.114105_bib12","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114105_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000539897","article-title":"Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.114105_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114105_bib15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/jama.2023.25394","article-title":"Lifting of embargoes to data sharing in clinical trials published in top medical journals","volume":"331","author":"Siebert","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ejca.2024.114105_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12916-022-02377-2","article-title":"Data-sharing and re-analysis for main studies assessed by the European Medicines Agency\u2013a cross-sectional study on European Public Assessment Reports","volume":"20","author":"Siebert","year":"2022","journal-title":"BMC Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924007615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924007615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T21:17:40Z","timestamp":1731878260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924007615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":16,"alternative-id":["S0959804924007615"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114105","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life in trials with high rates of early censoring: Caution advised","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114105"}}